Executive Summary / Key Takeaways

• Transformative Growth & Profitability: Owlet is undergoing a significant transformation, leveraging its unique FDA and CE medical clearances for Dream Sock and BabySat to drive record revenue growth and achieve five consecutive quarters of Adjusted EBITDA profitability, with full-year 2025 profitability now expected.
• Technological & Regulatory Moat: The company's core pulse oximetry technology, integrated into its smart socks and digital platform, provides medical-grade, real-time infant health insights, creating a strong competitive advantage in a market largely dominated by non-medical devices.
• Strategic Platform Expansion: Beyond hardware, Owlet is evolving into a comprehensive pediatric health platform through its rapidly growing Owlet360 subscription service (over 66,000 subscribers) and the Owlet Connect enterprise solution, aiming to extend customer lifetime value and integrate into clinical workflows.
• Strong Outlook Despite Headwinds: Despite macroeconomic uncertainties, including new tariffs impacting gross margins, Owlet has raised its full-year 2025 revenue guidance to $97 million to $100 million, signaling confidence in continued consumer demand and strategic execution.
• Capital Structure Simplification & Risks: Recent actions to simplify the capital structure through a warrant exchange are positive, though the company continues to address a "going concern" warning, customer concentration, and internal control weaknesses, which warrant close investor monitoring.

The Genesis of Peace of Mind: Owlet's Foundational Vision

Owlet, Inc. was founded in 2012 with a singular, powerful mission: to empower parents with real-time data and insights, ultimately providing medical-grade health monitors for use at home. This vision materialized with the launch of its first Smart Sock in 2016, pioneering the smart infant monitoring category. However, this journey was not without its trials, as the company faced significant regulatory scrutiny and legal challenges in 2021 regarding the FDA's classification of its Smart Sock.

These challenges proved to be a crucible, forging a more resilient and strategically focused company. The pivotal moment arrived in 2024 with the hard-won FDA clearance for both its Dream Sock and BabySat devices, immediately followed by CE Medical approval in Europe. This regulatory validation transformed Owlet, establishing it as the leader in a new category of medical-grade infant health monitors and setting the stage for its current growth trajectory.

The Technological Moat: Data, Devices, and Digital Health

Owlet's core competitive advantage lies in its differentiated technology and the regulatory approvals it has secured. The Dream Sock, a wearable infant health monitor, utilizes advanced pulse oximetry technology to track vital signs such as pulse rate, activity, oxygen level, and sleep patterns. This provides parents with real-time data and insights directly through the Owlet Care App, offering peace of mind that non-medical devices cannot match. The BabySat takes this a step further, functioning as an FDA-cleared, prescription-eligible medical device for high-risk infants, offering a wireless and wearable alternative to traditional, bulky hospital equipment. This innovation addresses a critical need for at-home monitoring for conditions like RSV, pneumonia, and bronchitis, targeting over 570,000 U.S. babies annually.

The company's commitment to innovation extends beyond hardware. The Owlet360 subscription service, launched in January 2025, leverages Owlet's extensive pediatric health and sleep dataset—amassed from millions of babies and trillions of heartbeats—to provide personalized, actionable insights. This service includes features like Sleep Position (launched Q2 2025), historical data trends (planned H2 2025), and a pilot for AI-generated sleep insights by year-end 2025. These advancements aim to offer caregivers personalized, data-backed guidance, enhancing the daily utility of the platform and driving long-term subscriber growth.

For the healthcare sector, Owlet Connect is an enterprise data integration platform designed to facilitate real-time sharing of BabySat data with healthcare providers. This platform integrates unique pediatric data into clinical workflows, electronic health records, and research databases. It enables neonatologists to receive real-time monitoring information from discharged NICU babies without altering their existing workflows, a groundbreaking development for remote patient monitoring. These technological differentiators collectively form a robust competitive moat, allowing Owlet to command a premium, enhance customer loyalty, and expand into new, high-margin revenue streams.

Redefining the Nursery: Market Leadership and Global Reach

Owlet's consumer products, particularly the Dream Sock and Dream Duo, continue to demonstrate robust market leadership. In Q2 2025, domestic sell-through for these products grew 37% year-over-year, contributing significantly to the company's largest first-half revenue performance in its history. This strong demand is reflected in leading indicators, with Dream Sock additions to registries (Amazon (AMZN), Babylist, Target (TGT)) increasing 54% year-over-year in Q2 2025. The company also achieved its most successful Amazon Prime Day in July, with total sell-through units up 72% year-over-year, ranking as the #1 seller in the baby monitor and baby safety categories.

The company's brand health remains strong, with Dream Sock's Net Promoter Score (NPS) consistently over 73. Owlet has also increased its share of total dollars spent on baby monitors, reaching approximately 31% in the six months ending September 2024, up from 23% in the same period of 2023. This growth is further supported by a broader industry trend, as the baby monitor category itself has seen its highest consumer spending in five years.

Internationally, Owlet is rapidly expanding its footprint. Despite a Q2 2025 revenue timing shift, international sell-through was up 33% year-over-year. The U.K. saw a record Amazon Prime Day with sell-through units up 144%, while France and Germany experienced impressive sell-through growth of over 200% and 100% year-over-year, respectively. The recent TGA certification for Dream Sock in Australia and New Zealand further paves the way for global expansion, tapping into a market of approximately 140 million babies born worldwide annually, with less than 3% currently having access to a Dream Sock.

Unlocking Healthcare: BabySat's Medical Frontier

The BabySat device represents Owlet's strategic entry into the lucrative and impactful healthcare market. This FDA-cleared, prescription-eligible monitor is designed for high-risk infants, a segment that includes over 570,000 U.S. babies annually. While revenue contribution from BabySat remains "inconsequential" in the near term, the long-term opportunity is substantial. Owlet is actively building out its medical distribution channels, having partnered with six Durable Medical Equipment (DME) manufacturers. These partnerships are crucial for expanding access and facilitating insurance reimbursement.

Significant progress has been made on the reimbursement front, with AdaptHealth (AHCO) now accepting Medicaid plans for BabySat in 29 states, up from 12 states earlier in 2025. Furthermore, Cigna (CI) has recognized BabySat as a single patient technology, simplifying the reimbursement process. The alliance with Children's Hospital of the King's Daughters (CHKD) is a key milestone, enabling babies to leave the hospital with an Owlet infant health monitor for the first time ever, with data integrated via Owlet Connect. This initiative serves as a critical reference point for future hospital partnerships, as the dialogue with other institutions has "picked up" since the CHKD announcement. The increasing recommendation of Dream Sock or BabySat by NICU neonatologists further validates the medical community's recognition of Owlet's unique value proposition.

The Subscription Engine: Owlet360 and the Future of Pediatric Care

The Owlet360 subscription service is central to the company's evolution from a hardware provider to a comprehensive pediatric health platform. This service leverages Owlet's vast pediatric data to offer personalized insights into health metrics, pulse rate, oxygen levels, movement, and comfort temperature. Parents can compare their baby's trends against a massive pediatric database, gaining daily and weekly insights into health and sleep patterns. This offering aims to empower parents to better manage their children's care at home, potentially reducing unnecessary healthcare visits.

The adoption of Owlet360 has been rapid and encouraging. Total paying subscribers recently surpassed 66,000 in Q2 2025, a significant increase from over 48,000 in Q1 2025 and 25,000 during its Q4 2024 beta launch. Early results show strong engagement, with an 85% retention rate after the first month and approximately 60% of subscribers engaging as daily active users. The initial attach rate for the January cohort was approximately 12% even before official marketing. The service is priced at an introductory $5.99 per month, with plans for additional features like historical data trends and AI-generated sleep insights by year-end 2025. A telehealth pilot is also targeted for Q4 2025, further enhancing the platform's utility. While international rollout of Owlet360 is planned for next year, the current focus is on optimizing the domestic offering. This subscription model is expected to drive predictable recurring revenue, significantly boost customer lifetime value, and strengthen Owlet's competitive differentiation against rivals who lack such a comprehensive, data-driven platform.

Financial Resilience and Strategic Execution

Owlet's financial performance reflects its strategic execution and operational improvements. In Q2 2025, the company reported revenue of $26.1 million, a 25.9% increase year-over-year, contributing to its largest first-half revenue in company history. Gross margins expanded to 51.3% in Q2 2025, an increase of 180 basis points year-over-year, marking the ninth consecutive quarter of year-over-year gross margin expansion. This improvement is attributed to higher revenue, a favorable product mix towards Dream Sock, improved fixed cost absorption, and lower direct product and fulfillment costs, with the Owlet360 subscription also contributing.
The company achieved its fifth consecutive quarter of Adjusted EBITDA profitability in Q2 2025, reporting $0.3 million. This demonstrates strong operating leverage, with Q2 operating expenses as a percentage of revenue decreasing to 58.7% from 60.4% in Q2 2024. While the reported net loss for Q2 2025 was $37.6 million, this was primarily due to a $34.8 million noncash mark-to-market adjustment related to common stock warrant liability; excluding this, the net loss would have been $2.8 million.

Liquidity remains a critical focus. As of June 30, 2025, Owlet had $21.8 million in cash and cash equivalents. The company has an accumulated deficit of $302.8 million and has experienced recurring operating losses and negative cash flows from operations since inception, leading to a "going concern" warning. However, recent financing activities, including a $9.8 million net proceeds from an equity offering in September 2024 and a $35 million debt restructuring, have bolstered its balance sheet.

Further, on August 7, 2025, Owlet announced an agreement to exchange Series A and Series B Warrants for an aggregate of 5.43 million newly issued common shares, a move aimed at simplifying its capital structure and reducing uncertainty.

Navigating Headwinds: Risks and the Path Forward

Despite significant progress, Owlet faces several pertinent risks. The "going concern" warning, stemming from historical operating losses and negative cash flows, underscores the ongoing need for prudent financial management and potential future capital raises. Customer concentration is another notable risk, with one customer accounting for 64% and 52% of net revenues for the three and six months ended June 30, 2025, respectively, and 68% of accounts receivable. This reliance on a single customer could expose the company to significant revenue volatility.

Material weaknesses in internal controls over financial reporting, including an ineffective control environment and issues with segregation of duties, inventory, accrued liabilities, debt/equity arrangements, sales returns, and IT general controls, present operational and financial reporting risks. The company is actively implementing remediation plans, but these efforts will incur future costs and require sustained focus.

Tariffs pose a direct threat to gross margins. In Q2 2025, tariffs had a $500,000 impact on gross profit. With confirmed tariff increases to 20% for Vietnam (camera products) and 19% for Thailand (sock and duo products) effective August 1, a 5% impact on gross margin is anticipated for Q4. Owlet is actively exploring manufacturing diversification to mitigate these impacts, but the situation remains fluid. The broader macroeconomic backdrop, including inflation and potential reduced consumer purchasing power, also presents a risk to demand for its products.

Outlook: Sustained Growth and Profitability

Owlet's management has expressed strong confidence in its future, reflected in its updated full-year 2025 guidance. The company has raised its revenue guidance to a range of $97 million to $100 million, representing 24% to 28% growth year-over-year. This outlook is primarily driven by continued strong consumer demand for Dream Sock and Dream Duo products. Management anticipates sequential revenue growth each quarter, with Q4 expected to be the strongest due to holiday promotional seasons and a shift in retailer purchasing patterns.

Despite the raised revenue forecast, full-year 2025 gross margin guidance has been reaffirmed at 46% to 50%. This reflects the expectation that the positive impact of higher revenues will be offset by the increased tariff costs. Crucially, Owlet now fully expects to achieve Adjusted EBITDA profitability for the full year 2025, a significant milestone that underscores its commitment to operational efficiency and sustainable growth. This profitability target is maintained even with the tariff headwinds, demonstrating the underlying strength of the core business and cost management efforts. It is important to note that the 2025 guidance does not assume any material revenue contribution from the nascent Owlet360 subscription service or BabySat, indicating conservative projections for these long-term growth drivers.

Conclusion

Owlet, Inc. stands at a pivotal juncture, having successfully transformed from a hardware innovator into a burgeoning pediatric health platform. Its hard-won FDA and CE medical clearances for Dream Sock and BabySat provide a unique regulatory and technological moat, differentiating it significantly in the competitive baby monitoring market. The company's strategic expansion into subscription services with Owlet360 and healthcare channels with BabySat and Owlet Connect promises to unlock substantial long-term value, extending customer relationships and leveraging its unparalleled pediatric data.

While challenges such as the "going concern" warning, customer concentration, and tariff impacts persist, Owlet's recent financial performance, marked by record revenue growth and consistent Adjusted EBITDA profitability, demonstrates strong operational execution. The raised full-year 2025 guidance, coupled with a commitment to profitability, signals a confident outlook. For investors, Owlet represents a compelling opportunity to participate in a company leveraging technological leadership and regulatory advantage to redefine infant health and safety, with a clear path towards sustainable, profitable growth in the years ahead.